340 related articles for article (PubMed ID: 10377220)
1. Novel multidrug resistance reversal agents.
Berger D; Citarella R; Dutia M; Greenberger L; Hallett W; Paul R; Powell D
J Med Chem; 1999 Jun; 42(12):2145-61. PubMed ID: 10377220
[TBL] [Abstract][Full Text] [Related]
2. Potent reversal of multidrug resistance by ningalins and its use in drug combinations against human colon carcinoma xenograft in nude mice.
Chou TC; Guan Y; Soenen DR; Danishefsky SJ; Boger DL
Cancer Chemother Pharmacol; 2005 Oct; 56(4):379-90. PubMed ID: 15875185
[TBL] [Abstract][Full Text] [Related]
3. Direct interaction between verapamil and doxorubicin causes the lack of reversal effect of verapamil on P-glycoprotein mediated resistance to doxorubicin in vitro using L1210/VCR cells.
Breier A; Drobná Z; Barancík M
Neoplasma; 1998; 45(4):248-53. PubMed ID: 9890669
[TBL] [Abstract][Full Text] [Related]
4. Reversal of multidrug resistance of cancer through inhibition of P-glycoprotein by 5-bromotetrandrine.
Jin J; Wang FP; Wei H; Liu G
Cancer Chemother Pharmacol; 2005 Feb; 55(2):179-88. PubMed ID: 15378274
[TBL] [Abstract][Full Text] [Related]
5. New purines and purine analogs as modulators of multidrug resistance.
Dhainaut A; Regnier G; Tizot A; Pierre A; Leonce S; Guilbaud N; Kraus-Berthier L; Atassi G
J Med Chem; 1996 Sep; 39(20):4099-108. PubMed ID: 8831775
[TBL] [Abstract][Full Text] [Related]
6. Design and synthesis of tetrahydroisoquinoline derivatives as potential multidrug resistance reversal agents in cancer.
Li Y; Zhang HB; Huang WL; Li YM
Bioorg Med Chem Lett; 2008 Jun; 18(12):3652-5. PubMed ID: 18502125
[TBL] [Abstract][Full Text] [Related]
7. Potentiation of etoposide and vincristine by two synthetic 1,4-dihydropyridine derivatives in multidrug-resistant and atypical multidrug-resistant human cancer cells.
Watanabe Y; Takano H; Kiue A; Kohno K; Kuwano M
Anticancer Drug Des; 1991 Feb; 6(1):47-57. PubMed ID: 2015041
[TBL] [Abstract][Full Text] [Related]
8. Antitumor agents. 3. Design, synthesis, and biological evaluation of new pyridoisoquinolindione and dihydrothienoquinolindione derivatives with potent cytotoxic activity.
Bolognese A; Correale G; Manfra M; Lavecchia A; Mazzoni O; Novellino E; La Colla P; Sanna G; Loddo R
J Med Chem; 2004 Feb; 47(4):849-58. PubMed ID: 14761187
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and antitumor evaluation of 2,5-disubstituted-indazolo[4, 3-gh]isoquinolin-6(2H)-ones (9-aza-anthrapyrazoles).
Krapcho AP; Menta E; Oliva A; Di Domenico R; Fiocchi L; Maresch ME; Gallagher CE; Hacker MP; Beggiolin G; Giuliani FC; Pezzoni G; Spinelli S
J Med Chem; 1998 Dec; 41(27):5429-44. PubMed ID: 9876113
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative.
Hyafil F; Vergely C; Du Vignaud P; Grand-Perret T
Cancer Res; 1993 Oct; 53(19):4595-602. PubMed ID: 8402633
[TBL] [Abstract][Full Text] [Related]
11. Potentiation of the antitumor activity by a novel quinoline compound, MS-209, in multidrug-resistant solid tumor cell lines.
Nakanishi O; Baba M; Saito A; Yamashita T; Sato W; Abe H; Fukazawa N; Suzuki T; Sato S; Naito M; Tsuruo T
Oncol Res; 1997; 9(2):61-9. PubMed ID: 9167187
[TBL] [Abstract][Full Text] [Related]
12. Reversal of P-glycoprotein associated multidrug resistance by new isoprenoid derivatives.
Hayashi M; Koike K; Rho MC; Kuwano M; Kishiye T; Komiyama K
Anticancer Drug Des; 2001; 16(4-5):255-60. PubMed ID: 12049484
[TBL] [Abstract][Full Text] [Related]
13. Substituted tetrahydroisoquinoline compound B3 inhibited P-glycoprotein-mediated multidrug resistance in-vitro and in-vivo.
Fang W; Li Y; Cai Y; Kang K; Yan F; Liu G; Huang W
J Pharm Pharmacol; 2007 Dec; 59(12):1649-55. PubMed ID: 18053326
[TBL] [Abstract][Full Text] [Related]
14. Characterization of tetrandrine, a potent inhibitor of P-glycoprotein-mediated multidrug resistance.
Fu L; Liang Y; Deng L; Ding Y; Chen L; Ye Y; Yang X; Pan Q
Cancer Chemother Pharmacol; 2004 Apr; 53(4):349-56. PubMed ID: 14666379
[TBL] [Abstract][Full Text] [Related]
15. (R,R)-2,2'-[1,2-ethanediylbis[imino(1-methyl-2,1-ethanediyl)]]- bis[5-nitro-1H-benz[de]isoquinoline-1,3-(2H)-dione] dimethanesulfonate (DMP 840), a novel bis-naphthalimide with potent nonselective tumoricidal activity in vitro.
Kirshenbaum MR; Chen SF; Behrens CH; Papp LM; Stafford MM; Sun JH; Behrens DL; Fredericks JR; Polkus ST; Sipple P
Cancer Res; 1994 Apr; 54(8):2199-206. PubMed ID: 8174127
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of anticancer effects of newly synthesized dihydropyridine derivatives in comparison to verapamil and doxorubicin on T47D parental and resistant cell lines in vitro.
Bazargan L; Fouladdel S; Shafiee A; Amini M; Ghaffari SM; Azizi E
Cell Biol Toxicol; 2008 Apr; 24(2):165-74. PubMed ID: 17805981
[TBL] [Abstract][Full Text] [Related]
17. Bisbibenzyl derivatives sensitize vincristine-resistant KB/VCR cells to chemotherapeutic agents by retarding P-gp activity.
Xi GM; Sun B; Jiang HH; Kong F; Yuan HQ; Lou HX
Bioorg Med Chem; 2010 Sep; 18(18):6725-33. PubMed ID: 20724170
[TBL] [Abstract][Full Text] [Related]
18. Antitumor activity of troxacitabine (Troxatyl) against anthracycline-resistant human xenografts.
Gourdeau H; Genne P; Kadhim S; Bibeau L; Duchamp O; Ouellet F; deMuys JM; Bouffard DY; Attardo G
Cancer Chemother Pharmacol; 2002 Dec; 50(6):490-6. PubMed ID: 12451476
[TBL] [Abstract][Full Text] [Related]
19. [Reversal of acquired resistance to vinca alkaloids and anthracycline antibiotics by calcium channel blockers and calmodulin inhibitors].
Tsuruo T
Gan To Kagaku Ryoho; 1984 Mar; 11(3 Pt 2):750-9. PubMed ID: 6585181
[TBL] [Abstract][Full Text] [Related]
20. Discovery and characterization of OC144-093, a novel inhibitor of P-glycoprotein-mediated multidrug resistance.
Newman MJ; Rodarte JC; Benbatoul KD; Romano SJ; Zhang C; Krane S; Moran EJ; Uyeda RT; Dixon R; Guns ES; Mayer LD
Cancer Res; 2000 Jun; 60(11):2964-72. PubMed ID: 10850444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
